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Abstract
Background—To study the association between functional single nucleotide polymorphisms
(SNPs) in candidate genes from oxidative stress pathways, and risk of radiation pneumonitis (RP)
in patients treated with thoracic radiation therapy (RT) for locally advanced lung cancer (LC).
Methods—We reviewed 136 patients treated with RT for LC between 2001 and 2007, and had
prior genotyping of functional SNPs in oxidative stress genes including superoxide dismutase 2
(SOD2; rs4880) and methylenetetrahydrofolate reductase (MTHFR; rs1801131, rs1801133). RP
events were retrospectively scored using the Common Terminology Criteria for Adverse Events,
version 4.0. Cox proportional hazard regression was performed to identify clinical variables and
genotypes associated with risk of grade ≥2 and grade ≥3 RP on univariate and multivariate
analysis. P-values were corrected for multiple hypothesis testing.
Results—With a median follow-up of 21.4 months, the incidence of ≥grade 2 RP was 29% and
≥grade 3 RP was 14%. On multivariate analysis, after adjusting for clinical factors such as
concurrent chemotherapy, and consolidation docetaxel, and lung dosimetric parameters such as
V20 and mean lung dose, MTHFR genotype (rs1801131; AA versus AC/CC) was significantly
associated with risk of ≥grade 2 RP (Hazard ratio [HR]: 0.37; 95% confidence interval [CI]:
0.18-0.76; p=0.006, corrected p=0.018) and ≥grade 3 RP (HR: 0.21; 95% CI: 0.06-0.70; p=0.01;
corrected p=0.03). SOD2 genotype was not associated with RP.
Conclusions—Our study showed an association between MTHFR genotype and risk of
clinically significant RP. Further study of MTHFR-related pathways may provide insight into the
mechanisms behind RP.
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Introduction
Radiation pneumonitis (RP) remains a significant barrier to radiation dose escalation to
achieve adequate local control in the treatment of locally advanced lung cancer (LC). While
technological advances in the delivery of thoracic radiation therapy (RT) including intensity-
modulated radiation therapy (IMRT) has allowed gradual dose escalation with potential
reduction in toxicity1, rates of clinically-evident locoregional recurrence remain relatively
high at 20-50% in randomized trials of definitive radiation with concurrent chemotherapy in
patients with non-small cell lung cancer (NSCLC)2-4. Further dose escalation may be
limited by the increasing risk of normal tissue toxicity, including RP.
In contemporary studies, the risk of symptomatic (grade 2-5) RP ranges from 10-30%5-9,
and may be associated with radiation dose, concurrent chemotherapy regimens, use of
consolidation docetaxel4, 10, and other clinical factors. Radiation dose to specific lung
volumes have been correlated with risk of pneumonitis including volume of lungs receiving
> 20 Gray (Gy; V20), > 5 Gy (V5), and mean lung dose (MLD)5, 8, 9. While these studies
have helped establish a series of clinically useful dosimetric cutoffs, there may be a
continuum of risk of normal tissue toxicity, which may be determined by the interaction
between the physical distribution of radiation dose in the lungs and underlying biological
factors in the patient.
The pathogenesis of radiation-induced lung injury is not completely understood, but may be
due to a combination of direct radiation cytotoxicity to normal lung tissue and secondary
inflammatory changes and fibrotic remodeling11. Thus, genetic variation in key genes in
DNA repair, inflammation and oxidative stress pathways may ameliorate or exacerbate the
effects of a given radiation dose to the lungs. Prior retrospective candidate gene studies in
patients treated with RT for LC have shown associations between risk of RP and single
nucleotide polymorphisms (SNPs) in the ataxia-telangiectasia mutated (ATM)12, XRCC1,
APEX113, and p5314 genes, key components in cellular signaling and repair response to
ionizing radiation, and transforming growth factor-beta (TGFB1), a cytokine involved in
fibrotic remodeling15. Another important class of genes that may play a role in the
pathogenesis of RP is oxidative stress pathways genes including superoxide dismutase 2,
which is involved in free radical scavenging, and methylenetetrahydrofolate reductase,
which is a key regulator of folate, homocysteine, thiol, methylation, and thymidine
metabolism.
In this study, we build upon the existing literature by screening for an association between
risk of RP and functional SNPs in candidate genes from oxidative stress pathways in a
retrospective cohort of patients treated with thoracic RT for LC.
Methods
Patients
As part of an institutional review board-approved prospective molecular epidemiology
protocol, peripheral blood was collected from patients diagnosed with either non-small cell
lung cancer (NSCLC) or small cell lung cancer (SCLC) who were seen at the Massachusetts
General Hospital from 1992 to present. The peripheral blood was collected as part of
successive candidate gene epidemiological studies to examine associations between
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functional SNPs and LC risk and outcomes16-18. Patient and demographic information were
collected at the time of recruitment, and informed consent was obtained to collect follow-up
data. More than 85% of eligible patients were recruited in this cohort.
Out of approximately 3982 patients who consented to the protocol between 1992 and 2009,
2334 had prior genotyping of functional SNPs in two candidate genes involved in oxidative
stress pathways as listed below. We limited our study to patients treated after 2001, when
our department and the hospital adopted widespread utilization of an electronic medical
record system that allowed more accurate retrospective collection of clinical data. Out of
this group, we retrospectively identified 243 patients who were treated at MGH between
2001 and 2007 with thoracic RT with a minimum dose of 40 Gy. Of these 243 patients, we
excluded non-white patients (n=8), patients who were not treated with 3-dimensional
conformal RT (3D-CRT) or IMRT and did not have radiation dosimetric data for the lungs
(n=57), patients with stage I disease (n=18), patients who were lost to follow-up (<1 month
of follow-up) after treatment (n=7), and patients withinsufficient peripheral blood for
genotyping (n=10). The remaining 136 patients constituted our sample set for this RP and
candidate gene SNP association study.
Genotyping
Blood samples were collected from all study participants at the time of recruitment.
Germline DNA was isolated from the peripheral blood of each patient using Autopure blood
purification kits (Qiagen Sciences, Inc., Germantown, MD, USA). Genotyping was
performed using the 5′-nuclease assay (TaqMan) assay and the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA ,USA) on known
functional SNPs for candidate genes in oxidative stress pathways including: 1) superoxide
dismutase 2 (SOD2; 5482C>T, Val16Ala, rs4880); 2) methylenetetrahydrofolate reductase
(MTHFR; 1298A>C, Glu429Ala, rs1801131; and 677C>T, Ala222Val, rs1801133).
Genotyping was performed by laboratory personnel blinded to patient status, and a random
5% of the samples were repeated to validate genotyping procedures. Hardy-Weinberg
equilibrium was tested using the χ2 test. Due to the small sample sizes and small number of
patients with the homozygous variant genotypes, genotypes were primarily analyzed using
the dominant effects model (SOD2, rs4880: CC vs. CT/TT; MTHFR, rs1801131: AA vs.
AC/CC; MTHFR, rs1801133: CC vs. CT/TT).
Clinical and Radiation Dosimetric Covariates
Clinical covariates that may be associated with RP were retrospectively collected including,
patient age, ECOG performance status (PS), smoking status, pulmonary function test data,
AJCC TNM stage (6th edition), tumor size, RT technique, radiation dose, use of concurrent
or consolidation chemotherapy, use of consolidation docetaxel, and use of surgery. Smoking
status was categorized as: 1) never smokers; < 100 cigarettes in their lifetime; 2) former
smokers; quit >1 year prior to diagnosis, and 3) current smokers; smoking at the time of
diagnosis or quit < 1 year prior. Lung dosimetric variables including MLD, V5, and V20
were collected from the treatment plans. The lung volume was defined as the total volume of
the two lungs minus the volume of the gross tumor volume.
Endpoints
RP events were identified retrospectively and graded using the Common Terminology
Criteria for Adverse Events, (CTCAE version 4.0) by two of the investigators (B.M.A. and
R.H.M). Both investigators were blinded from the genotyping results and independently
reviewed all of the follow-up notes for each patient, and reviewed pertinent radiological
imaging to determine a diagnosis and grade of RP. The RP scores from the two investigators
were compared using the kappa statistic to estimate the concordance of grading, and any
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discordant results were reconciled. The RP grades were analyzed as dichotomized variables
at clinically relevant cutoffs: ≥grade 2 RP (use of steroids) versus grade 0-1 RP and ≥grade
3 RP (oxygen requirement) versus grade 0-2 RP. RP was analyzed as a time dependent
variable, and was calculated from the initiation of radiation therapy to the time when
patients had a RP event or were censored at the time of last follow-up or death.
Statistical Analysis
The cumulative incidence of RP was estimated using the Kaplan-Meier Method. Cox
proportional hazard models were performed to identify clinical variables and genotypes
associated with risk of RP on univariate and multivariate analysis. For multivariate analysis,
variables with a p-value < 0.10 were included in initial models as potential confounders.
Stepwise selection was performed to identify variables associated with ≥grade 2 or ≥grade 3
RP. Clinically important confounders such as lung dosimetric parameters were re-introduced
into the final model. Since 3 different SNPs were examined, we corrected for multiple
hypothesis testing using the method of Benjamini and Hochberg in both univariate and
multivariate analyses19. All statistical testing was done with a two-sided p-value < 0.05
level. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patient, Treatment and Radiation Dosimetric Characteristics
The median age of the patients was 67 (range, 37-85), 51% were female, 90% were current
or former smokers, and 95% had ECOG PS of 0-1 (Table 1). In the 118 patients with
pulmonary function testing, the median FEV1 was 1.98 L (range, 0.66-4.31 L). The majority
of patients were treated with definitive RT without surgery (78%), and the remainder
received RT preoperatively (11%) or postoperatively (11%). In total, 96% of patients
received chemotherapy, including as induction prior to RT (8%), concurrently with RT
(89%) and for consolidation after RT (57%). Of note, 12% of patients received consolidation
docetaxel. All patients were treated with IMRT (75%) or 3D-CRT (25%). The median
prescribed dose was 63 Gy (range, 41.4-72.7). Dosimetric parameters for the lungs included
a median V20 of 34% (9.4-70%), V5 of 51% (14-93%) and MLD of 18.1 Gy (6.1-32.4 Gy).
MTHFR and SOD2 Genotyping
The distribution of the MTHFR (rs1801131 and rs1801133) and SOD2 genotypes are shown
in Table 2. All MTHFR and SOD2 polymorphisms examined were in Hardy-Weinberg
equilibrium (p > 0.05, χ2 goodness of fit).
Radiation Pneumonitis
With a median follow-up of 21.4 months (range, 1.6-109.5 months) after initiation of RT,
the crude incidence of ≥grade 2 RP was 29% (40/136) with an 1-year Kaplan-Meier estimate
of 30.5%, and the crude incidence of ≥grade 3 RP was 14% (19/136)with an 1-year Kaplan-
Meier estimate of 13.7%. There was excellent concordance between the two independent
measures of RP grade using CTCAE version 4.0 with a kappa statistic of 0.81 (95%
confidence interval [CI]: 0.72-0.90) when examining the scores on an ordinal scale from 0 to
5. When examining the RP grading as a dichotomous variable of ≥grade 2 and ≥grade 3, the
kappa statistics were 0.96 (95% CI: 0.92-1.0) and 0.94 (95% CI: 0.85-1.0), respectively. In
total, two cases were discordant between the two independent measures of RP as a
dichotomous variable for both ≥grade 2 and ≥grade 3.
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Clinical and Dosimetric Variables Associated with RP
On univariate analysis (Table 3), clinical variables associated with ≥grade 2 RP included
gender, performance status, MLD, and use of surgery. On multivariate analysis, gender,
ECOG PS, surgery, concurrent chemotherapy, and consolidation docetaxel were associated
with ≥grade 2 RP (Table 4). Important dosimetric predictors of RP including MLD, V20 and
V5 were re-introduced into the final model. The continuous variables such as MLD, V20
and V5 were analyzed both continuously and as categorical variables (e.g. dichotomized at
the median); since the models were not significantly different with either approach, the
dichotomized variable analysis models are presented.
Univariate and Multivariate Analysis of SNP Association with RP
The MTHFR 1298A>C SNP (rs1801131) was associated with risk of ≥grade 2 RP on
univariate analysis with a hazard ratio (HR) of 0.51 (95% CI: 0.27-0.97; p=0.04; corrected
p=0.12) for the MTHFR 1298 AC/CC versus AA genotype (Table 3). Kaplan-Meier
estimates of the incidence of ≥grade 2 RP at 12 months from the initiation of RT were
39.3% for patients with the MTHFR 1298 AA genotype versus 22.3% for patients with the
MTHFR 1298 AC/CC genotypes (Figure 1A). Analysis of the MTHFR 1298 genotypes
using a co-dominant model (AA vs. AC vs. CC) showed a significant decrease in risk of RP
between 1298 AA versus AC genotype, and a non-significant decrease in risk of 1298 AA
versus CC genotype on both univariate and multivariate analysis (Table 4). Genotype of
SOD2 (rs4880), and the other SNP from the MTHFR gene (rs1801133; 677C>T) were not
significantly associated with risk of ≥grade 2 RP on univariate analysis (Table 3).
After adjusting for potential clinical and dosimetric confounders, there remained an
association between ≥grade 2 RP and MTHFR 1298A>C genotype (rs1801131; 1298AA vs.
AC/CC) with an adjusted hazard ratio (AHR) of 0.37 (95% CI: 0.18-0.76; p=0.006;
corrected p=0.018; Table 4). Neither the SOD2 nor the other MTHFR (rs1801133) SNP
were associated with risk of ≥grade 2 RP on multivariate analysis (Table 4).
We also examined the relationship between the MTHFR 1298C>A SNP and risk of ≥grade 3
RP (Table 5). Kaplan-Meier estimates of the incidence of ≥grade 3 RP at 12 months from
the initiation of RT were 22.0% for patients with the MTHFR 1298AA genotype versus
5.7% for patients with the MTHFR 1298AC/CC genotypes (Figure 1B). MTHFR 1298 AC/
CC versus AA genotype were significantly associated with decreased risk of ≥grade 3 RP on
univariate analysis (HR: 0.30; 95% CI: 0.11-0.83, p=0.02; corrected p=0.06), and
multivariate analysis (AHR: 0.21; 95% CI: 0.06-0.70; p=0.01; corrected p=0.03).
Discussion
In this cohort of patients treated with thoracic RT for lung cancer, we explored the
association between RP and SNPs from candidate genes in oxidative stress pathways. We
identified an association between risk of RP and the MTHFR 1298A>C genotype
(rs1801131). Patients with AC/CC genotypes had a lower risk of both ≥grade 2 and of
≥grade 3 RP compared to patients with the wild-type AA genotype. This association was
seen after adjusting for clinical and dosimetric variables associated with risk of RP, and
correcting for multiple testing. Patients with an MTHFR 1298AC/CC genotype had an
unadjusted incidence of ≥grade 2 RP of only 17%, compared to 50% in patients with an AA
genotype, raising the hypothesis that AC/CC genotype may be protective. Furthermore, the
adjusted hazard ratios of 0.37 (95% CI: 0.18-0.76; p=0.006; corrected p=0.018) and 0.21
(95% CI: 0.06-0.70; p=0.01; corrected p=0.03), for ≥grade 2 RP and ≥grade 3 RP,
respectively, may suggest a strong underlying biological effect. While there was not a strong
association between decreased risk of both 1298AC and 1298CC genotype independently
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versus 1298AA nor a variant allele dose effect (i.e. a decrease in risk of RP with each
additional C allele), the small sample size in the 1298CC genotype subtype (n=13) likely
makes this an underpowered analysis and such a dose effect cannot be excluded. Thus,
further work in confirming this hypothesis-generating finding in a larger cohort of patients
will be of interest.
The MTHFR 1298A>C SNP (rs1801131) results in a glutamate to alanine substitution at
codon 439 in exon 7, which is located in the COOH-terminal regulatory domain of the gene,
and results in a 30-40% reduction of enzymatic function in the homozygous variant
genotype20. The MTHFR enzyme plays a central role in the intersection between a number
of important metabolic pathways including folate metabolism, thymidine synthesis,
homocysteine processing, and synthesis of both sulfhydrl- and methyl-donating species.
MTHFR is a pivotal enzyme in cell metabolism by catalyzing the irreversible conversion of
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate; the latter is used in methionine
synthesis (a key precursor in DNA methylation), while the former is a key building block in
thymidine synthesis that is catalyzed by the thymidylate synthase enzyme, and thus may
play an important role in DNA repair. Of interest, Batra et al. demonstrated that after total
body irradiation in mice, MTHFR activity levels decreased while thymidylate synthase
activity increased suggesting that the regulation of these enzymes in diverting folate
metabolism toward thymidine base synthesis may play an important role in the cellular
response to ionizing radiation21. Our study identifies an increased risk of RP with the AA
genotype, which is associated with higher MTHFR enzymatic function and may potentially
lower both levels of thiol and thymidine synthesis. Thus, further work to study whether risk
of RP is associated with genes involved in these related pathways of thiol, methyl, and
pyrimidine synthesis may be of interest.
Strengths of this study include the relative genetic homogeneity of the population, which
was achieved by including only white patients to reduce the influence of variation in
genotype distribution by race. Secondly, by including only patients with locally advanced
lung cancer, the majority received chemotherapy and were treated with similar radiation
techniques. Furthermore, by including only patients that received treatment with modern
3D-CRT and IMRT techniques, we were able to control for known dosimetric predictors of
RP such as MLD, V5 and V20. Of note, these previously established lung dosimetric
parameters were not significantly associated with RP on multivariate analysis in our dataset.
The lack of association between MLD, V5, and V20 and RP may be due to the heterogeneity
of treatment techniques including IMRT and 3D-conformal RT, use of surgery and use of
chemotherapy. Additionally, some of the patients in our series were treated during a time
period after publications regarding V5, V20 and MLD had been published,5-8, and may have
led to adjustment of clinical practice to meet these new clinical constraints, which would
confound the predictive ability of these parameters. However, since the main goal of this
study was to identify SNPs associated with RP, controlling for clinical and dosimetric
variables as potential confounders of the primary analysis was important, but the
independent predictive ability of these variables are less important.
The findings of this study must be interpreted in the context of its retrospective design. First,
retrospective assessment of radiation-related toxicity is often difficult due to incomplete
follow-up and reliance on physician documentation of these events, which may be biased
and/or incompletely documented. To address these challenges, we utilized the CTCAE RP
grading system dichotomized at clinically relevant endpoints, which allowed us to assess for
RP based on the use of medical interventions (e.g. steroids) for ≥grade 2 RP or new oxygen
requirement for ≥grade 3 RP. Furthermore, we used two independent retrospective reviews
of the patients’ records to generate the RP grades, and had a high concordance rate in the
two scores, which suggests consistency in how these events were documented in the medical
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records at our institution and subsequently interpreted retrospectively. A second limitation
was that the study had a relatively modest number of patients and events, and thus validation
in a larger data set will be required. Third, there was heterogeneity in clinical factors that
could impact both the risk and/or the retrospective scoring of RP. For example, the use of
surgery could certainly impact both the risk of RP and post-operative declines in pulmonary
function may impact the ability to reliably score RP. However, we controlled for surgery
and other clinical factors in our multivariate model, and we had stringent criteria for scoring
RP with highly concordant independent measures of the endpoint as discussed above.
Fourth, the rates of RP in this series are fairly high, particularly since the majority of these
patients were treated with IMRT which may reflect further heterogeneity such as differences
in techniques during the early adoption of IMRT, the use of concurrent chemotherapy, and
the use of consolidation docetaxel in some patients, but the high event rate does increase the
power of this data set to detect associations with the genotypes studied. Additionally, while
the MTHFR 1298A>C (rs1801131) was associated with the risk of RP, a second MTHFR
SNP (rs1801133; 677C>T) was not associated with RP in the test and validation cohorts.
This inconsistency may be due to insufficient power in this study to detect an association
with the other SNP, different function of these two MTHFR SNPs or greater biological
effect of the 1298A>C versus the 677C>T SNP. Furthermore, there are numerous other
SNPs in the SOD2 and MTHFR gene that were not analyzed in this study, and verification
of the results of this study will include further study of other polymorphisms in these genes.
Finally, as is the case for most candidate gene studies, the finding of an association between
RP and the MTHFR SNP (rs1801131) may represent a role of the MTHFR gene in
mediating the response of lung tissue to radiation injury or alternatively the SNP may simply
be a marker for another gene that is in linkage disequilibrium with the SNP. Thus, to further
validate these findings, the functional relationship between the MTHFR pathway and risk of
RP must be determined, such as by assessment of downstream products of the pathway
including homocysteine and thymidine. Nevertheless, this study is the first to our knowledge
to identify a potential association between a functional SNP in the MTHFR gene and risk of
radiation-related toxicity.
The results of our study build upon prior published RP and candidate gene association
studies. Prior retrospective studies from MD Anderson and Beijing have identified an
association between risk of RP and the pro-fibrotic cytokine, TGF-β, and DNA damage
response and repair genes: ATM, p53, APEX1, and XRCC112-15. Of note, the Beijing
studies were conducted in a Chinese population of 253, while the MD Anderson study was
conducted in a population of 164 patients of several different races. While these studies
highlighted the potential importance of circulating cytokines and DNA repair in the risk of
RP, we identified a novel association between RP and the MTHFR gene, which may provide
new insights into the biological mechanisms of radiation injury. However, we did not
observe an association between RP and a SNP in the important oxidative stress gene SOD2
(rs4880). In all the studies to date, the effect estimate of the genotypes found to have an
association with ≥grade 2 RP has been relatively large, which is likely a reflection of the
relatively small sample sizes in all these studies. All of these cohorts are likely
underpowered to detect SNPs with relatively minor biological effects in modulating the risk
of RP. For instance, in a post-hoc power calculation for our study, with the sample size of
136 patients and a null hypothesis of a rate of RP of 29%, our study is underpowered to
detect an association between RP and a SNP that would confer a less than 11% change in the
rate of RP at the 80% level with an alpha level of 0.05. Furthermore, differences in the
patient cohorts in each of these institutional studies including genetic variations due to race
may make cross-validation and/or pooling of data sets difficult to interpret. The challenge
facing the field of radiation oncology will be to improve the prospective gathering of
radiation-induced toxicity events, in conjunction with collection of tissue and genetic
material.
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Conclusions
Our study showed an association between risk of clinically significant RP after radiation
therapy for lung cancer and MTHFR genotype (1298AA vs. AC/CC; rs1801131). Further
validation work including association studies with other enzymes involved in folate
metabolism may identify new biomarkers for risk of RP.
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Condensed abstract
This is a candidate gene study examining the association between single nucleotide
polymorphisms in oxidative stress genes and radiation pneumonitis in a retrospective
cohort of patients treated with thoracic radiation therapy for lung cancer. There was an
association between methylenetetrahydrofolate reductase (MTHFR) genotype and risk of
clinically significant radiation pneumonitis.
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Figure 1.
Kaplan-Meier Plots of Cumulative (A) ≥Grade 2 and (B) ≥Grade 3 Radiation Pneumonitis in
Patients with MTHFR 1298 AA (gray line) versus 1298 AC/CC Genotype (black line).
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Table 1
Patient, tumor and treatment characteristics.
All Patients (n=136) Grade 0-1 RP (n=96) ≥Grade 2 RP (n=40) ≥Grade 3 RP (n=19)
Patient Characteristics
Median Age (range) 66.7 (37.2-85.2) 66.8 (37.2-85.3) 61.4 (48.0-83.7) 63.9 (51.2-83.4)
Male 67 (49.3%) 41 (42.7%) 26 (65.0%) 15 (79.0%)
Female 69 (50.7%) 55 (57.3%) 14 (35.0%) 4 (21.0%)
ECOG PS
 0 62 (45.6%) 45 (46.9%) 17 (42.5%) 7 (36.8%)
 1 67 (49.3%) 49 (51.0%) 18 (45.0%) 9 (47.4%)
 2 7 (5.1%) 2 (2.1%) 5 (12.5%) 3 (15.8%)
Smoking Status
 Current 48 (35.3%) 37 (38.5%) 11 (27.5%) 6 (31.6%)
 Former 74 (54.4%) 48 (50.0%) 26 (65.0%) 12 (63.2%)
 Never 14 (10.3%) 11 (11.5%) 3 (7.5%) 1 (5.3%)
Median Pack-years (range) 49 (0-200) 49 (0-200) 40 (0-150) 55 (0-120)
Median FEV1 in Liters (range) 1.98 (0.66-4.31;
n=115)
1.99 (0.74-4.31; n=81) .98 (0.66-3.44; n=34) .98 (0.92-3.44;
n=18)
Tumor Characteristics
Histology:
 Squamous cell carcinoma 29 (21.3%) 19 (19.8%) 10 (25.0%) 5 (26.3%)
 Adenocarcinoma 64 (47.1%) 49 (51.0%) 15 (37.5%) 5 (26.3%)
 Poor differentiated carcinoma† 28 (20.6%) 17 (17.7%) 11 (27.5%) 7 (36.8%)
 Small cell lung cancer 15 (11.0%) 11 (11.5%) 4 (10.0%) 2 (10.5%)
T-stage
 0 6 (4.4%) 4 (4.2%) 2 (5.0%) 2 (10.5%)
 1 31 (22.8%) 26 (27.1%) 5 (12.5%) 1 (5.3%)
 2 47 (34.6%) 30 (31.2%) 17 (42.5%) 8 (42.1%)
 3 24 (17.6%) 15 (15.6%) 9 (22.5%) 4 (21.0%)
 4 28 (20.6%) 21 (21.9%) 7 (17.5%) 4 (21.0%)
N-stage
 0 10 (7.4%) 10 (10.4%) 0 (0.0%) 0 (0.0%)
 1 11 (8.1%) 10 (10.4%) 1 (2.5%) 0 (0.0%)
 2 80 (58.8%) 53 (55.2%) 27 (67.5%) 14 (73.7%)
 3 35 (25.7%) 23 (24.0%) 12 (30.0%) 5 (26.3%)
Stage
 IIB 9 (6.6%) 9 (9.4%) 0 (0.0%) 0 (0.0%)
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All Patients (n=136) Grade 0-1 RP (n=96) ≥Grade 2 RP (n=40) ≥Grade 3 RP (n=19)
 IIIA 63 (46.3%) 40 (41.7%) 23 (57.5%) 11 (57.9%)
 IIIB 52 (38.2%) 38 (39.6%) 14 (35.0%) 7 (36.8%)
 IV 12 (8.8%) 9 (9.4%) 3 (7.5%) 1 (5.3%)
Treatment Characteristics
Median Radiation Dose (range) 63 Gy (41.4-72.7) 63 Gy (45-72) 66.6 Gy (41.4-72.7) 66.6 Gy (41.4-72.7)
Radiation Technique:
 3D Conformal 34 (25%) 26 (27.1%) 8 (20.0%) 2 (10.5%)
 IMRT 102 (75%) 70 (72.9%) 32 (80.0%) 17 ( 89.5%)
Simulation Technique:
 3D-CT 72 (52.9%) 53 (55.2%) 19 (47.5%) 8 (42.1%)
 4D CT 64 (47.1%) 43 (44.8%) 21 (52.5%) 11 (57.9%)
Radiation Sequencing:
 Pre-operative 15 (11.0%) 13 (13.5%) 2 (5.0%) 0 (0.0%)
 Radiation alone 106 (78.0%) 69 (71.9%) 37 (92.5%) 19 (100%)
 Post-operative 15 (11.0%) 14 (14.6%) 1 (2.5%) 0 (0.0%)
Surgery 30 (22.8%) 27 (28.1%) 3 (7.5%) 0 (0.0%)
Surgery Type
 Wedge 4 (13.3%) 4 (14.8%) 0 -
 Lobectomy 25 (83.3%) 22 (81.5%) 3 (100%) -
 Pneumonectomy 1 (3.3%) 1 (3.7%) 0 -
Any Chemotherapy 130 (95.6%) 91 (94.8%) 39 (97.5%) 18 (94.7%)
Induction Chemotherapy 11 (8.1%) 10 (10.4%) 1 (2.5%) 1 (5.3%)
Concurrent Chemotherapy 121 (89.0%) 82 (85.4%) 39 (97.5%) 18 (94.7%)
Consolidation Chemotherapy 78 (57.4%) 54 (56.3%) 24 (60.0%) 5 (26.3%)
Consolidation Docetaxel 16 (11.8%) 9 (8.3%) 8 (20.0%) 3 (15.8%)
Bilateral Lung Dose-Volume
Histogram
 Median V5 (range) 61.7% (21.7-97.2%) 59.4% (21.7-95.0%) 65.3% (38.0 - 97.2%) 63.8% (42.0-97.2%)
 Median V20 (range) 34.0% (9.4-70.0%) 32.4% (9.6-68.7%) 36.3% (21.9-70.0%) 36.4% (22.0-68.0%)
 Median MLD (range) 18.1 Gy (6.1-32.4 Gy) 17.6 Gy (6.1-29.3 Gy) 19.8 Gy (11.0-32.4 Gy) 20.5 (13.3-32.4 Gy)
†
Includes carcinoma not otherwise specified (NOS) and non-small cell lung cancer NOS.
Abbreviations: CT=computed tomography; FEV1=force expiratory volume in 1 second; IMRT=intensity modulated radiation therapy;
MLD=mean lung dose; PS=performance status; V5=volume receiving greater than 5 Gy; V10=volume receiving greater than 10 Gy; V20=volume
receiving greater than 20 Gy; RP=radiation pneumonitis.
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Table 2
Genotype Frequency
Single Nucleotide Polymorphisms All Patients(n=136)
Grade 0-1 RP
(n=96)
≥Grade 2 RP
(n=40)
≥Grade 3 RP
(n=19)
MTHFR (rs1801131)*
  AA 61 (45.5%) 38 (40.0%) 23 (59.0%) 13 (72.2%)
 AC 60 (44.8%) 48 (50.5%) 12 (30.8%) 3 (11.1%)
 CC 13 (9.7%) 9 (9.5%) 4 (10.3%) 2 (16.7%)
AC/CC 73 (54.5%) 57 (60.0%) 16 (41.0%) 5 (27.8%)
MTHFR (rs1801133)*
  CC 51 (38.1%) 40 (42.1%) 11 (28.2%) 4 (22.2%)
 CT 59 (44.0%) 40 (42.1%) 19 (48.7%) 8 (44.4%)
 TT 24 (17.9%) 15 (15.8%) 9 (23.1%) 6 (33.3%)
CT/ TT 83 (61.9%) 55 (57.9%) 28 (71.8%) 14 (77.7%)
SOD2 (rs4880)
  TT 32 (23.5%) 21 (21.9%) 11 (27.5%) 6 (31.6%)
 TC 76 (55.9%) 51 (53.1%) 25 (62.5%) 9 (47.4%)
 CC 28 (20.6%) 4 (25.0%) 4 (10%) 4 (21.0%)
  TC/CC 104 (76.5%) 72 (78.1%) 29 (72.5%) 13 (68.4%)
*
Data available on 134 patients
Abbreviations: RP=radiation pneumonitis.
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